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BACKGROUND: Understanding variation in stage at diagnosis can inform interventions to improve the timeliness of diagnosis for patients
with different cancers and characteristics.
METHODS: We analysed population-based data on 17 836 and 13 286 East of England residents diagnosed with (female) breast and
lung cancer during 2006–2009, with stage information on 16 460 (92%) and 10 435 (79%) patients, respectively. Odds ratios (ORs)
of advanced stage at diagnosis adjusted for patient and tumour characteristics were derived using logistic regression.
RESULTS: We present adjusted ORs of diagnosis in stages III/IV compared with diagnosis in stages I/II. For breast cancer, the frequency
of advanced stage at diagnosis increased stepwise among old women (ORs: 1.21, 1.46, 1.68 and 1.78 for women aged 70–74,
75–79, 80–84 andX85, respectively, compared with those aged 65–69 , Po0.001). In contrast, for lung cancer advanced stage at
diagnosis was less frequent in old patients (ORs: 0.82, 0.74, 0.73 and 0.66, Po0.001). Advanced stage at diagnosis was more frequent
in more deprived women with breast cancer (OR: 1.23 for most compared with least deprived, P¼ 0.002), and in men with lung
cancer (OR: 1.14, P¼ 0.011). The observed patterns were robust to sensitivity analyses approaches for handling missing stage data
under different assumptions.
CONCLUSION: Interventions to help improve the timeliness of diagnosis of different cancers should be targeted at specific age groups.
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Increasing the proportion of cancer patients who are diagnosed in
early stage could help decrease the number of cancer-related
deaths (Abdel-Rahman et al, 2009). Therefore, national cancer
control policies in several countries currently encompass initia-
tives supporting early detection and diagnosis (Olesen et al, 2009;
Richards, 2009; Coleman et al, 2011).
The evidence base supporting these initiatives, however, is
complex and heterogeneous (Richards, 2009). Markers and
measures of the timeliness of diagnosis currently in use include
short-term survival (NCIN (National Cancer Intelligence Network),
2008a; Møller et al, 2009; Rachet et al, 2009), diagnosis after an
emergency hospital admission (NCIN (National Cancer Intelli-
gence Network), 2010), and length of time intervals between
symptom onset and diagnosis (Neal and Allgar, 2005; Macleod
et al, 2009; Olesen et al, 2009). Stage at diagnosis is an excellent
measure of early detection, but UK population-based data
regarding this measure are limited. A recent National Audit Office
report indicated that the completeness of stage information
across English cancer registries is o40% (NAO (National Audit
Office), 2010).
A better understanding of socio-demographic variation in stage
at diagnosis could help stratify and tailor symptom awareness and
early diagnosis interventions aimed at specific patient groups.
We distinguish between ‘stratification’ that is, the targeting of an
intervention to patient populations at a higher risk and ‘tailoring’,
that is, the adaptation (or customising), a generic intervention
to make its application more suitable for specific patient groups.
An example of this concept relates to targeted interventions
to increase breast cancer symptom awareness amongst older
women (Forbes et al, 2011). It can also help focus early diagnosis
audit efforts (RCGP (Royal College of General Practitioners), 2011)
towards the cancers and patient groups with greatest potential for
improvement.
Against this background, we have set out to examine socio-
demographic variation in stage at diagnosis for female breast and
lung cancers (two common cancers responsible for about 30%
of all cancer diagnoses and cancer deaths in England (NCIN
(National Cancer Intelligence Network), 2008b) during a recent
period.
MATERIALS AND METHODS
Data
We analysed information on the stage at diagnosis of East
of England patients diagnosed with female breast (‘breast’
hereafter) and lung cancer during the 4-year period 2006–2009
(International Classification of Diseases (ICD)-10 codes C50
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and C34, respectively). The study period was chosen as the most
recent for which data were available at the time of analysis.
Anonymous data were extracted from the Eastern Cancer
Registration and Information Centre (ECRIC), a population-based
cancer registry covering a general population ofB5.7 million. The
Registry has excellent performance as indicated by conventional
measures of cancer registration quality such as death-certificate
only registrations (B0%) and, uniquely at present among other
English cancer registries, it holds information on stage at diagnosis
for a particularly high proportion of patients (NAO (National
Audit Office), 2010). Stage at diagnosis was classified using the 5th
edition of the TNM classification, comprising stages I–IV (Sobin
and Wittekind, 1997). Stage at diagnosis was assigned by CHB and
BR, integrating clinical, imaging and pathological information.
Patient socioeconomic status was ascribed using the income
domain of the Index of Multiple Deprivation (IMD) 2004
deprivation score of the Lower Super Output Area (LSOA) of
patients’ residence in order to define quintile groups (1¼ least
deprived, or ‘most affluent’; 5¼most deprived) (Office of the
Deputy Prime Minister, 2004). The income domain of IMD 2004
incorporates information on the proportion of residents of a small
area who live in households receiving state-funded support
(for example, in the form of income support, unemployment
benefit and tax credits). Tumour histological type was categorised
into seven groups for breast (infiltrating ductal carcinoma, lobular
carcinoma, mixed ductal lobular, other adenocarcinoma, other
specified carcinoma, specified not carcinoma tumours and other
unspecified) and eight for lung cancer (adenocarcinoma, squa-
mous cell carcinoma, other non-small cell, small cell carcinoma,
large cell carcinoma, carcinoid, other specified and other
unspecified), using appropriate ICD-Oncology morphology codes
(WHO (Word Health Organisation), 2000).
Analysis
We aimed to examine socio-demographic variation in advanced
stage at diagnosis.
Initial analysis was confined to patients with known stage
(complete case analysis). Binary logistic regression was used,
defining advanced stage at diagnosis both as diagnosis in stages
III/IV, or alternatively as diagnosis in stages II–IV (that is,
diagnosis other than in stage I). For brevity, we present findings
regarding variation in diagnosis in stages III/IV (vs I–II) in the
main paper and append analysis relating to diagnosis at stage I (vs
II–IV). We considered, but did not use, ordinal logistic regression
because initial analysis provided evidence of violation of the
proportional odds assumption.
Mixed-effects logistic regression models were used to predict
advanced stage at diagnosis, adjusting for age group, deprivation
quintile and tumour type (both cancers), sex (lung cancer) and
screening detection status (breast cancer) as fixed effect categorical
variables and including a random effect for Primary Care Trust.
Although the UK government plans to abolish Primary Care Trusts
in the future, they were responsible for planning, purchasing and
quality assuring preventive services and primary or specialist
health care for their residents during the study period (2006–
2009). A model using only fixed effect variables for patient
characteristics would assume that all observations are indepen-
dent. In reality, patients within the same organisation may be more
similar. Therefore, the models used recognise the hierarchical
nature of the data, with patient-level observations being nested
within Primary Care Trusts. Therefore, they provided information
about patient-level variation (for example, between patients
of different age, sex or deprivation status) without the risk of
identifying spurious associations arising from potential clustering
of different patient subgroups in Primary Care Trusts with higher
or lower rates of advanced stage at diagnosis. To explore a
potential interaction between age and sex for lung cancer, we have
included in a subsequent model an interaction variable for age
category (continuous) by sex.
Significance testing was principally based on joint log likelihood
ratio tests. We specifically focused aspects of the analysis on
patients aged 470 years of age because in recent decades
improvements in cancer survival in this age group were smaller
compared with those observed in younger patients, a finding
thought to partially reflect relatively more advanced stage at
diagnosis amongst older patients (Quaglia et al, 2009). Therefore,
in addition to testing the overall effect of age, we also examined the
significance of differences between patients X70 years compared
with patients in all other age groups. Further, tests for linear
trend were used to examine the significance of deprivation group
gradients by treating deprivation quintile as continuous rather
than a categorical variable.
Sensitivity analysis Complete case analysis may be biased, depending
on the mechanism responsible for missing data, that is, if data are
not ‘missing completely at random’ (MCAR) (Appendix Table A1).
(Sterne et al, 2009). Therefore, in addition, we have used two different
sensitivity analysis approaches for handling potential bias arising
from missing stage information, bearing in mind different assump-
tions about the potential mechanisms generating missing data.
First, we used multiple imputation to impute stage. Multiple
imputation is a method increasingly used in the context cancer
epidemiological studies (He et al, 2008; Nur et al, 2010; Ali et al,
2011). It assumes that data are ‘missing at random’ (MAR), that is,
that any systematic differences between the missing and observed
values can be estimated using information from the observed data
(note: the MAR assumption does not mean that there are no
systematic associations between missing data and specific
variables) (Appendix Table A1). We included in imputation
models survival, tumour histological grade, basis of diagnosis
(that is, whether the diagnosis was verified with histology or not),
Primary Care Trust and oestrogen receptor status (breast cancer
imputation models only) in addition to all the variables used in
the analysis models. All exposure variables used in either the
analysis or imputation models were complete, except for grade
and oestrogen receptor status (used in imputation models).
Second, as it is not possible to verify the MAR assumption
empirically, we conducted sensitivity analysis with a more extreme
imputation of missing stage that falls under the assumption of data
‘missing not at random’ (MNAR) (Appendix Table A1). To do this,
we assigned all patients with unknown stage to the advanced stage
category (III/IV), and repeated the analysis. This extreme case
scenario approach is based on observations that the survival of
patients with missing stage information is typically similar to that
of patients diagnosed in advanced stage (ECRIC (Eastern Cancer
Registration and Information Centre), 2011). We do not expect this
extreme case scenario to represent a true situation, but we use it to
illustrate how sensitive the complete case and multiple imputation
analyses may be to the MCAR or MAR assumptions, respectively.
All analysis was conducted in STATA 11 (StataCorp. 2009, College
Station, TX, USA), including using the ice and mim commands
used for multiple imputation (Royston, 2007). Further details are
provided in Appendix Table A1.
RESULTS
Data relate to 17 836 and 13 286 patients with incident diagnosis
of breast and lung cancer. Information on stage at diagnosis
was complete for 16 460 (92%) and 10 435 (79%) patients. The
completeness of stage information varied substantially between
patients with different socio-demographic characteristics and
tumour types – missing stage was more frequent in older patients
in particular (Po0.001 for both cancers, Appendix Table A2).
Among staged patients with breast and lung cancer, 41% and 15%
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were diagnosed in stage I, and 86% and 21% in stages I/II,
respectively (Table 1).
Multivariate complete case analysis
Breast cancer There was very strong evidence of an association
between age and diagnosis in stages III/IV, (Table 2). Specifically
for women aged X70 years, the frequency of diagnosis in stages
III/IV increased progressively with older age (odds ratios (ORs):
1.21, 1.46, 1.68 and 1.78 for women aged 70–74, 75–79, 80–84 and
X85 years, respectively, Po0.001). Increasing deprivation was
associated with a greater frequency of stage III/IV diagnosis (joint
log likelihood ratio P¼ 0.010, p for trend¼ 0.002; Table 2).
Lung cancer There was very strong evidence of an association
between age and advanced stage at diagnosis (Table 3). The
frequency of stage III/IV diagnosis decreased progressively among
patients aged X70 years (ORs: of 0.82, 0.74, 0.73 and 0.66 for
patients aged 70–74, 75–79, 80–84 and X85 years, respectively,
Po0.001). There was no evidence for deprivation group differ-
ences in lung cancer diagnosis at stages III/IV, in spite of an
apparent trend towards lower frequency with increasing depriva-
tion (p for trend¼ 0.236) (Table 3). There was strong evidence
of a higher frequency of advanced stage at diagnosis in men (odds
ratio of 1.14 for diagnosis in stages III/IV, P¼ 0.011). There was no
evidence for a differential effect of age in men and women (OR for
men vs women per increase in age group category¼ 0.96, 95% CI
0.92–1.01, P¼ 0.100). Although this may reflect lack of power,
the size of the interaction indicates that a large synergistic effect is
unlikely.
Examining variation in diagnosis in stage I vs II–IV produced
overall similar findings for lung cancer. For breast cancer, the findings
were similar in respect of variation in older age, but there was no
evidence of deprivation differences (Appendix Tables A3 and A4).
Sensitivity analysis Repeating the analysis using multiple im-
putation of missing stage information produced highly similar
values and patterns to those derived by the complete case analysis
(Tables 4 and 5). Specifically, for both breast and lung cancer the
same patterns of variation by age, deprivation and sex (for lung
cancer only) were apparent. Repeating the analysis using the
extreme case scenario approach (missing stage¼ advanced stage)
produced similar patterns of variation for lung cancer. For breast
cancer, in the extreme case scenario that the true stage at diagnosis
of all women with missing information was either stage III or IV,
deprivation differences in advanced stage at diagnosis would be
smaller. The full output from all analysis models is provided in
Appendix Table A5.
DISCUSSION
Summary of findings and comparisons with other
literature
Using population-based data, we identified substantial socio-
demographic variation in the stage at diagnosis of breast and lung
cancer. Breast cancer patients who were X70 years of age had a
higher frequency of advanced stage at diagnosis. Conversely, age
X70 was associated with a lower frequency of advanced stage at
diagnosis for lung cancer. Advanced stage at diagnosis was more
frequent in more deprived patients with breast cancer. Men with
lung cancer had a higher frequency of advanced stage at diagnosis.
Table 1 Proportion of patients by stage, gender, age and deprivation
group categories for breast and lung cancer (2006–2009)
Breast Lung
N
% among
all
patients
% among
patients
with
known
stage N
% among
all patients
% among
patients
with
known
stage
Stage
Stage I 6788 38% 41% 1534 12% 15%
Stage II 7361 41% 45% 670 5% 6%
Stage III 1490 8% 9% 3483 26% 33%
Stage IV 821 5% 5% 4748 36% 46%
Unknown 1376 8% n/a 2851 21% n/a
Sex
Men n/a 7684 58%
Women 17 836 100% 5602 42%
Age groupa
15–39 770 4%
40–44 1091 6% n/a
45–49 1539 9%
15–49 n/a 380 3%
50–54 2048 11% 443 3%
55–59 1911 11% 903 7%
60–64 2461 14% 1525 11%
65–69 2152 12% 1762 13%
70–74 1491 8% 2166 16%
75–79 1590 9% 2384 18%
80–84 1321 7% 2099 16%
X85 1462 8% 1624 12%
Deprivation group
Affluent 4778 27% 2471 19%
2 4658 26% 3072 23%
3 4323 24% 3444 26%
4 3081 17% 3072 23%
Deprived 996 6% 1227 9%
aYounger age groups were categorised differently for the two examined cancers
because compared with breast cancer there were fewer patients with lung cancer
in the younger age groups.
Table 2 Breast cancer. Independent associations of age and deprivation
with advanced stage at diagnosis (i.e., stage III/IV vs stage I/II)a (n¼ 16 460)
Odds
ratio
Lower
95%
confidence
interval
Higher
95%
confidence
interval P
15–39 1.15 0.89 1.48
40–44 1.02 0.81 1.28
45–49 0.91 0.74 1.14
50–54 0.92 0.74 1.14
55–59 0.90 0.72 1.12
60–64 0.91 0.74 1.12
65–69 Reference o0.001b (o0.001)c
70–74 1.21 0.98 1.49
75–79 1.46 1.20 1.78
80–84 1.68 1.37 2.07
X85 1.78 1.45 2.18
Most affluent Reference 0.010b (0.002)d
2 1.16 1.02 1.32
3 1.12 0.98 1.28
4 1.29 1.12 1.49
Deprived 1.23 1.00 1.52
aFrom logistic regression models, with stage III/IV vs stage I/II diagnosis as the binary
outcome variable. Models were adjusted for age, deprivation, tumour type and
diagnosis through screening or symptomatically, and included a random effect for
Primary Care Trust. bFrom joint log likelihood test for effect of age or deprivation as
applicable. cFrom joint log likelihood ratio tests for significance of difference between
patients aged X70 years and patients in all other age groups. dFrom models with
deprivation quintile group entered as a continuous variable.
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The findings were robust to multiple imputation of missing stage
(under the MAR assumption). Similar patterns of variation were
also observed for extreme case scenario analysis (under the MNAR
assumption of missing stage¼ advanced stage), except that
deprivation differences in advanced stage diagnosis for breast
cancer were smaller.
Regarding age differences in stage at diagnosis, no apparent age
patterns were apparent in a recent analysis of the US breast cancer
data (CDC, 2010). For lung cancer, evidence from Denmark
indicates a lower frequency of advanced stage at diagnosis with
increasing age, as observed in our own study (Dalton et al, 2011).
For breast cancer, the observed socioeconomic differences
concord with other evidence from the United Kingdom, United
States and Canada, indicating a higher frequency of advanced stage
at diagnosis among women of lower socioeconomic position.
(Adams et al, 2004; Clegg et al, 2009; Cuthbertson et al, 2009;
Booth et al, 2010). For lung cancer, studies from Canada, Denmark
and Sweden have indicated only limited socioeconomic differences
in advanced stage at diagnosis (Berglund et al, 2010; Booth et al,
2010; Dalton et al, 2011). A previous UK study reported lower
frequency of advanced stage at diagnosis in more deprived patients
(Brewster et al, 2001). The findings of our study are similar with
previous UK research, although there was no independent
evidence of an association (P for trend¼ 0.236) that may reflect
the lack of power.
Strengths and limitations
The principal strengths of the study are its population-based
design, and the high quality and completeness of information on
stage at diagnosis and other tumour variables. Unlike previous
studies in this field, we adjusted the analysis for tumour subtype
and employed sensitivity analyses approaches using different
assumptions about potential mechanisms responsible for missing
stage data. Previous studies on stage at diagnosis of breast cancer
did not encompass adjustment for screening or symptomatic
detection status, and this factor complicated the interpretation of
age and socioeconomic differences in stage at diagnosis (Macleod
et al, 2000; Adams et al, 2004; Cuthbertson et al, 2009). In contrast,
our findings indicate that substantial age and deprivation
differences in stage at diagnosis of breast cancer exist indepen-
dently of whether a woman was diagnosed by screening or after
symptomatic presentation. A previous UK study on stage at
diagnosis of lung cancer only reported on socioeconomic
differences (not encompassing age and sex differences) in the
mid-1990s (Brewster et al, 2001). Therefore, we believe the findings
enrich substantially the currently available evidence on patterns of
stage at diagnosis in patients with breast and lung cancer.
The study also has certain limitations. We could not adjust the
analysis for ethnicity – a potential confounder of deprivation in
particular. During the study period, the proportion of East of
England residents belonging to ethnic minorities was relatively
small, particularly among persons X65 years (where the majority
of cancer cases occur); B97% of the East of England resident
population in this age group were estimated as being British White
in 2007 (ONS (Office for National Statistics), 2009). Given the
demographic characteristics of the East of England population, the
Table 4 Breast cancer. Summary of outputs obtained by complete case
analysis and sensitivity analyses (odds ratios for stage III/IV vs I/II).
Complete
case analysisa
Multiple
imputation
Missing
stage¼ II – IV
15–39 1.15 1.13 1.08
40–44 1.02 1.01 0.85
45–49 0.91 0.91 0.85
50–54 0.92 0.90 0.93
55–59 0.90 0.88 0.81
60–64 0.91 0.90 0.86
65–69 Reference
70–74 1.21 1.23 1.08
75–79 1.46 1.49 1.30
80–84 1.68 1.74 1.77
X85 1.78 1.84 2.21
Most affluent Reference
2 1.16 1.20 1.12
3 1.12 1.16 1.07
4 1.29 1.32 1.21
Deprived 1.23 1.27 1.07
aThis column replicates information included in Table 2 – presented here for ease
of comparisons.
Table 5 Lung cancer. Summary of outputs obtained by complete case
analysis and sensitivity analyses (odds ratios for stage III/IV vs I/II)
Complete
case analysisa
Multiple
imputation
Missing
stage¼ stage
II – IV
Women Reference
Men 1.14 1.13 1.15
15–49 1.33 1.23 1.31
50–54 1.00 0.96 0.95
55–59 1.26 1.22 1.23
60–64 0.96 0.95 0.95
65–69 Reference
70–74 0.82 0.80 0.82
75–79 0.74 0.72 0.75
80–84 0.73 0.73 0.78
X85 0.66 0.68 0.76
Most affluent Reference
2 0.94 0.97 0.95
3 0.97 1.01 0.97
4 0.98 1.04 0.99
Deprived 0.81 0.91 0.82
aThis column replicates information included in Table 3 – presented here for ease
of comparisons.
Table 3 Lung cancer. Independent associations of age, deprivation and
sex with advanced stage diagnosis (i.e., stage III/IV vs stage I/II)a (n¼ 10 435)
Odds
ratio
Lower 95%
confidence
interval
Higher 95%
confidence
interval P
Women Reference 0.011b
Men 1.14 1.03 1.25
15–49 1.33 0.93 1.90 o0.001b (o0.001)c
50–54 1.00 0.74 1.35
55–59 1.26 0.99 1.61
60–64 0.96 0.79 1.18
65–69 Reference
70–74 0.82 0.68 0.97
75–79 0.74 0.62 0.88
80–84 0.73 0.61 0.88
X85 0.66 0.54 0.81
Most affluent Reference 0.290b (0.236)d
2 0.94 0.81 1.09
3 0.97 0.83 1.12
4 0.98 0.84 1.14
Deprived 0.81 0.66 0.99
aFrom logistic regression models, with stage II – IV vs stage I or stage III/IV vs stage I/II
diagnosis as the binary outcome variable. Models were adjusted for age, sex,
deprivation and tumour type, and included a random effect for Primary Care Trust.
bFrom joint log likelihood test for effect of sex, age or deprivation as applicable. cFrom
joint log likelihood ratio tests for significance of difference between patients aged
X70 years and patients in all other age groups. dFrom models with deprivation
quintile group entered as a continuous variable.
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findings can be considered to chiefly describe socio-demographic
variation in stage at diagnosis among White British patients.
Nevertheless, examination of patterns of stage at diagnosis by
ethnic group is warranted in the future.
We examined data from a single region that includes about 10%
of the total English population. Socioeconomic differences in
short-term cancer survival, however, (a marker of early diagnosis)
are relatively similar across different English regions (Rachet et al,
2009). Inequalities in cancer treatment patterns observed in East of
England cancer patients are also similar to those observed
nationwide (Wishart et al, 2010). These considerations indicate
that the observed socio-demographic patterns of stage at diagnosis
can be applicable to the rest of the English population. The size of
the East of England population (B5.7 million) is similar to that of
several European countries.
In common with previous authoritative UK research (Brewster
et al, 2001; Adams et al, 2004; Rachet et al, 2010), we used an area-
based measure of socioeconomic status in our study, relating to
the population characteristics of highly homogeneous small
areas (LSOA) (Woods et al, 2005). Socioeconomic status can be
measured either directly (for example, by measuring a person’s
income, occupation or education) or indirectly (ecologically) by
measuring the characteristics of the population of a small area
(Liberatos et al, 1988). Both direct and area-based measures of
socioeconomic status have limitations (Sloggett et al, 2007), and
might be affected by lack of homogeneity within groups (for
example, between patients of the same social class, income,
education or neighbourhood) (Carstairs and Morris, 1989). Using
an area-based measure of socioeconomic status may have either
underestimated or overestimated socioeconomic gradients in stage
at diagnosis compared with direct measures (Sloggett et al, 2007),
and research examining such gradients using both area-based and
direct measures would be useful.
Interpretation and research policy implications
A key consideration in interpreting the findings is whether the
observed variation in advanced stage at diagnosis, particularly in
relation to age, can be considered avoidable. In theory, the findings
might in part reflect differences in the malignant potential of
tumours between patients of different ages. The analysis was,
however, adjusted for tumour subtype. This makes it less likely
that age differences in tumour biology can be responsible for
major part of the observed age differences in stage at diagnosis.
For breast cancer, it is possible that the observed variation in
stage at diagnosis reflects differences in the awareness of cancer
symptoms between different patient groups. Awareness of cancer
symptoms and signs in the United Kingdom is socio-demogra-
phically patterned, and is lower among individuals aged 465 and
of lower socioeconomic status (Robb et al, 2009). The findings of
the study would support the targeting of breast cancer awareness
interventions at older women (Forbes et al, 2011).
The lower frequency of advanced stage at diagnosis among older
lung cancer patients could reflect more frequent use of chest X ray
investigations in older patients (for example, in the context of
investigating either a chest infection or other clinical presentations
such as shortness of breath). A recent population study from
Denmark indicated a lower frequency of advanced stage lung
cancer diagnosis among patients with higher levels of comorbidity
and also (as observed in our study) with increasing age (Dalton
et al, 2011). Another potential explanation is that ‘stage for stage’
lung cancer is more symptomatic in older patients, for example,
either because of a higher propensity to present with concomitant
chest infection (prompting earlier investigation and leading
to earlier diagnosis) or earlier presentation of dyspnoea because
of physiologically declining lung capacity in older age. Further
research in this area is clearly needed to explore the validity of
these hypotheses, and to identify the mechanisms responsible for
excess risk of advanced stage at diagnosis in relatively younger
patients.
There was a substantial excess risk of advanced stage at
diagnosis among breast cancer women X70 years of age. These
differences should not be dismissed as clinically unimportant; in
our study sample, one-third of women with breast cancer were
aged X70 years. In the United Kingdom, life expectancy for
women aged 70 and 80 year-old is 16.5 and 9.5 years, respectively
(ONS (Office for National Statistics), 2011). Decreasing the
frequency of advanced stage at diagnosis among women X70
years can therefore contribute substantially to reducing avoidable
mortality in this age group. In contrast, the findings also identify
opportunities for achieving earlier stage diagnosis of lung cancer
in relatively young patients (for example, those aged 60–74 years).
CONCLUSION
There is substantial potential for improvements in early diagnosis
in older patients with breast cancer and in relatively younger
patients with lung cancer. The findings could help guide breast and
lung cancer early diagnosis initiatives and research focused on
individuals of different age groups at highest risk of advanced
stage at diagnosis. These could, for example, encompass age
stratified and tailored cancer symptoms awareness interventions,
or educational interventions for physicians and healthcare
professionals, targeted at patients of different age groups. We
provide an exemplar of how population-based cancer registration
information could help support national initiatives aimed at
improving early diagnosis, and inform further policy and research.
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APPENDIX
Further details on imputation
We used the STATA ice command for multiple imputation (see
reference by Royston et al (2007) of main paper). For (female)
breast cancer, imputation models included information on age,
deprivation, tumour type, screening detection status, tumour grade,
oestrogen receptor status, histological verification status, Primary
Care Trust and survival. For lung cancer, imputation models
included information on age, sex, deprivation, tumour type,
tumour grade, histological verification status and Primary Care
Trust and survival.
Stage was treated as a binary variable (stage III/IV vs I/II). Grade
was treated as an ordinal variable with four levels for colorectal
and lung cancer, and three levels for breast cancer. All other
variables except for survival were treated as categorical. For
survival we used the Nelson–Aalen estimate of the cumulative
hazard function along with an indicator variable describing vital
status at end of follow-up.
Informed by considerations of the proportion of missing data
for different variables, 50 imputed data sets were generated for either
cancer. All imputed data sets were each analysed separately and then
combined using Rubin’s rules, using the STATA mim command.
Analysis models on the imputed data sets included the same
variables as those used in the analysis models using the complete
case analysis approach, that is, age, deprivation, tumour type and
screening detection status for breast cancer, and age, sex,
deprivation and tumour type for lung cancer, including a random
effect for Primary Care Trust.
Table A1 Additional details on methods of sensitivity analysis and
imputation. Potential mechanisms responsible for missing stage data
Assumed mechanism
How each assumption relates to
the analysis in this paper
’Missing completely at random’ (MCAR):
there are no systematic differences
between the missing values and the
observed values.
‘Complete case analysis’ will give
unbiased (although less precise)
estimates under the MCAR assumption.
Said differently, complete case analysis
implicitly assumes that data are ‘missing
completely at random’. Although this
assumption does not hold (we know
that stage is more likely to be missing in
older patients), the potential for bias is
minimised by the high level of
stage data completeness.
‘Missing at random’ (MAR): any
systematic difference between the
missing and observed values can be
explained by differences in observed
data. Under this assumption, although
patients with missing stage information
may have a higher probability of being
diagnosed in advanced stage compared
with patients with observed stage, this
probability can be estimated from the
associations of stage with age, sex,
tumour type and so on among patients
with observed stage.
The assumption that stage data are
‘missing at random’ underpins sensitivity
analysis using multiple imputation. This
assumption becomes more reasonable
by also including in imputation models
variables other than those used in the
analysis models (e.g., survival, grade and
basis of diagnosis).a
‘Missing not at random’ (MNAR): even
after information from patients with
observed stage and its associations with
other variables are taken into account,
systematic differences remain between
patients with missing and observed
stage. For example, because more
advanced stage at diagnosis is more
likely to remain unobserved.
The assumption that stage data are
‘missing not at random’ underpins
sensitivity analysis using substitution of
unknown stage values with advanced
stage. We do not expect this extreme
case scenario to be true, but it illustrates
how sensitive the complete case and
multiple imputation analyses may be to
the MCAR or the MAR assumptions,
respectively.
aWhen only outcome data are missing (e.g., on patient stage), complete case analysis
will give unbiased estimates under the assumption that data are ‘missing at random’
when the missing outcome is dependent only on variables included in the analysis
model. This assumption is more reasonable than the ‘missing completely at random’
one, but may still not hold; however, it can become even more reasonable by
including additional variables in the imputation models, as applied in this study.
Table A2 Predictors of missing stage
Total Staged % staged p (v2)
(a) Breast cancer
Affluent 4778 4385 92 0.490a
2 4658 4321 93
3 4323 4007 93
4 3081 2809 91
Deprived 996 938 94
15–39 770 709 92 o0.001b
40–44 1091 1036 95
45–49 1539 1437 93
50–54 2048 1930 94
55–59 1911 1832 96
60–64 2461 2350 95
65–69 2152 2036 95
70–74 1491 1393 93
75–79 1590 1458 92
80–84 1321 1133 86 o0.001c
X85 1462 1146 78
Infiltrating ductal carcinoma 12 826 12 030 94 o0.001b
Lobular carcinoma 2099 1922 92
Mixed ductal lobular 1211 1164 96
Other adenocarcinoma 709 653 92
Other specified carcinoma 89 79 89
Other unspecified 863 609 71
Specified not carcinoma 39 3 8
All patients 17 836 16 460 92
(b) Lung cancer
Men 5602 4392 78 0.736a
Women 7684 6043 79
Affluent 2471 1900 77 0.009b
2 3072 2402 78
3 3444 2734 79
4 3072 2397 78
Deprived 1227 1002 82
15–49 380 287 76 o0.001a
50–54 443 359 81
55–59 903 743 82
60–64 1525 1248 82
65–69 1762 1416 80
70–74 2166 1759 81
75–79 2384 1899 80
80–84 2099 1597 76 o0.001c
X85 1624 1127 69
Adenocarcinoma 2366 1901 80 o0.001a
Carcinoid 100 16 16
Large cell carcinoma 145 128 88
Other non-small cell 2475 2117 86
Small cell carcinoma 1464 1150 79
Specified other 10 2 20
Squamous cell carcinoma 2351 2040 87
Unspecified other 4375 3081 70
All patients 13 286 10 435 79
(a) aFrom univariate logistic regression for stage completeness, with deprivation
quintile group entered as a continuous exposure variable. bFrom w2-test. cFrom log
likelihood ratio tests for significance of difference between the ‘older’ age groups
(i.e. age groupsX70 years) and other age groups. (b) aFrom w2-test. bFrom univariate
logistic regression for stage completeness, with deprivation quintile group entered as a
continuous variable. cFrom log likelihood ratio tests for significance of difference between
the ‘older’ age groups (i.e., age groups X70 years) and other age groups.
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Table A3 Findings in relation to variation in breast cancer diagnosis at
stage I vs stages II– IV
Stage II-IV vs stage I
Odds
ratio
Lower 95%
confidence
interval
Higher 95%
confidence
interval P
Breast cancer
15–39 2.04 1.69 2.47 o0.001a
40–44 1.67 1.42 1.96
45–49 1.57 1.35 1.81
50–54 1.30 1.14 1.48
55–59 1.23 1.08 1.41
60–64 1.06 0.93 1.20
65–69 Reference
70–74 1.45 1.25 1.67 (o0.001b)
75–79 1.70 1.47 1.97
80–84 1.99 1.69 2.34
X85 2.41 2.04 2.86
Most affluent Reference 0.335a
2 1.03 0.94 1.13 (0.172c)
3 1.03 0.94 1.13
4 1.11 1.00 1.24
Deprived 1.00 0.86 1.17
Independent associations of age and deprivation with diagnosis in stage I vs II – IVd
(n¼ 16 460) aFrom joint log likelihood test for effect of age or deprivation as
applicable. bFrom joint log likelihood ratio tests for significance of difference between
patients aged X70 years and patients in all other age groups. cFrom models with
deprivation quintile group entered as a continuous variable. dFrom logistic regression
models, with diagnosis in stage II – IV vs stage I as the binary outcome variable. Models
were adjusted for age, deprivation, tumour type and diagnosis through screening or
symptomatic presentation, and included a random effect for Primary Care Trust.
Table A4 Findings in relation to variation in lung cancer diagnosis at
stage I vs stages II–IV
Complete case
analysis
Multiple
imputation
Missing stage¼
stage III/IV
OR
95%
LCI
95%
UCI OR
95%
LCI
95%
UCI FMI OR
95%
LCI
95%
UCI
Women Ref. — — Ref. — — — Ref. — —
Men 1.14 1.03 1.25 1.13 1.03 1.25 0.170 1.15 1.05 1.27
15–49 1.33 0.93 1.90 1.23 0.86 1.75 0.197 1.31 — —
50–54 1.00 0.74 1.35 0.96 0.71 1.30 0.157 0.95 0.93 1.84
55–59 1.26 0.99 1.61 1.22 0.96 1.55 0.119 1.23 0.71 1.27
60–64 0.96 0.79 1.18 0.95 0.78 1.16 0.150 0.95 0.97 1.56
65–69 Ref. — — Ref. — — — — 0.78 1.15
70–74 0.82 0.68 0.97 0.80 0.68 0.96 0.109 0.82 0.69 0.98
75–79 0.74 0.62 0.88 0.72 0.60 0.86 0.171 0.75 0.64 0.89
80–84 0.73 0.61 0.88 0.73 0.61 0.87 0.16 0.78 0.65 0.93
X85 0.66 0.54 0.81 0.68 0.55 0.83 0.23 0.76 0.62 0.92
Most affluent Ref. — — Ref. — — — Ref. — —
2 0.94 0.81 1.09 0.97 0.84 1.12 0.138 0.95 0.82 1.10
3 0.97 0.83 1.12 1.01 0.87 1.17 0.184 0.97 0.84 1.12
4 0.98 0.84 1.14 1.04 0.89 1.21 0.209 0.99 0.86 1.15
Deprived 0.81 0.66 0.99 0.91 0.75 1.10 0.186 0.82 0.67 0.99
Adenocarcinoma Ref. — — Ref. — — — Ref. — —
Squamous cell carcinoma 0.91 0.79 1.05 0.89 0.77 1.02 0.116 0.83 0.72 0.95
Other non-small cell types 2.07 1.77 2.42 1.97 1.70 2.29 0.099 1.87 1.61 2.18
Small cell carcinoma 4.06 3.23 5.12 3.90 3.10 4.92 0.207 3.94 3.14 4.94
Large cell carcinoma 1.51 0.97 2.36 1.44 0.93 2.22 0.065 1.29 0.83 1.99
Carcinoid 0.02 0.00 0.18 0.02 0.00 0.15 0.764 1.53 0.87 2.70
Specified other 0.41 0.03 6.63 0.74 0.06 9.27 0.627 2.30 0.29 18.35
Unspecified other 1.94 1.67 2.24 1.85 1.59 2.15 0.289 2.07 1.80 2.37
Abbreviations: OR¼ odds ratio; Ref¼ reference; LCI¼ lower confidence interval;
UCI¼ upper confidence interval; FMI¼ fraction of missing information (for each
respective variable category, it denotes the proportion of the estimation that used
imputed missing information).
Table A5 Full outputs of all analysis models presented in main paper
(for stage III/IV vs I/II comparisons)
Complete case
analysis
Multiple
imputation
Missing stage¼
stage III/IV
OR
95%
LCI
95%
UCI OR
95%
LCI
95%
UCI FMI OR
95%
LCI
95%
UCI
(a) Breast cancer, stage III/IV vs stage I – II
15 – 39 1.15 0.89 1.48 1.13 0.88 1.46 0.062 1.08 0.87 1.34
40 – 44 1.02 0.81 1.28 1.01 0.80 1.27 0.069 0.85 0.70 1.05
45 – 49 0.91 0.74 1.14 0.91 0.73 1.13 0.088 0.85 0.70 1.02
50 – 54 0.92 0.74 1.14 0.90 0.72 1.11 0.066 0.93 0.78 1.11
55 – 59 0.90 0.72 1.12 0.88 0.71 1.09 0.058 0.81 0.67 0.98
60 – 64 0.91 0.74 1.12 0.89 0.73 1.10 0.076 0.86 0.72 1.02
65 – 69 Ref. Ref. Ref.
70 – 74 1.21 0.98 1.49 1.22 0.99 1.50 0.064 1.08 0.90 1.29
75 – 79 1.46 1.20 1.78 1.50 1.23 1.82 0.062 1.30 1.09 1.54
80 – 84 1.68 1.37 2.07 1.75 1.43 2.15 0.115 1.77 1.49 2.10
X85 1.78 1.45 2.18 1.86 1.52 2.27 0.128 2.21 1.87 2.62
Most affluent Ref. Ref. Ref.
2 1.16 1.02 1.32 1.20 1.05 1.36 0.107 1.12 1.00 1.25
3 1.12 0.98 1.28 1.16 1.02 1.32 0.091 1.07 0.95 1.19
4 1.29 1.12 1.49 1.32 1.15 1.52 0.116 1.21 1.07 1.36
Deprived 1.23 1.00 1.52 1.27 1.03 1.57 0.149 1.07 0.89 1.29
Infiltrating ductal carcinoma Ref. Ref. Ref.
Lobular carcinoma 1.59 1.39 1.81 1.62 1.42 1.84 0.061 1.54 1.38 1.73
Mixed ductal lobular 1.09 0.90 1.32 1.10 0.91 1.33 0.051 0.97 0.82 1.15
Other adenocarcinoma 0.99 0.79 1.25 0.98 0.78 1.23 0.058 0.99 0.82 1.20
Other specified carcinoma 0.58 0.26 1.26 0.58 0.27 1.27 0.118 0.90 0.52 1.54
Other unspecified 3.90 3.26 4.66 4.01 3.37 4.77 0.254 4.57 3.93 5.32
Specified not carcinoma 3.57 0.28 46.04 1.78 0.14 22.25 0.870 81.48 19.36 342.93
Screening detection
status- no
Ref.
Screening detection
status-yes
0.26 0.22 0.31 0.27 0.22 0.32 0.030 0.20 0.17 0.24
(b) Lung cancer, odds ratios of stage III/IV vs stage I/II
Women Ref. Ref. Ref.
Men 1.14 1.03 1.25 1.13 1.03 1.25 0.170 1.15 1.05 1.27
15 – 49 1.33 0.93 1.90 1.23 0.86 1.75 0.197 1.31
50 – 54 1.00 0.74 1.35 0.96 0.71 1.30 0.157 0.95 0.93 1.84
55 – 59 1.26 0.99 1.61 1.22 0.96 1.55 0.119 1.23 0.71 1.27
60 – 64 0.96 0.79 1.18 0.95 0.78 1.16 0.150 0.95 0.97 1.56
65 – 69 Ref. Ref. 0.78 1.15
70 – 74 0.82 0.68 0.97 0.80 0.68 0.96 0.109 0.82 0.69 0.98
75 – 79 0.74 0.62 0.88 0.72 0.60 0.86 0.171 0.75 0.64 0.89
80 – 84 0.73 0.61 0.88 0.73 0.61 0.87 0.16 0.78 0.65 0.93
X85 0.66 0.54 0.81 0.68 0.55 0.83 0.23 0.76 0.62 0.92
Most affluent Ref. Ref. Ref.
2 0.94 0.81 1.09 0.97 0.84 1.12 0.138 0.95 0.82 1.10
3 0.97 0.83 1.12 1.01 0.87 1.17 0.184 0.97 0.84 1.12
4 0.98 0.84 1.14 1.04 0.89 1.21 0.209 0.99 0.86 1.15
Deprived 0.81 0.66 0.99 0.91 0.75 1.10 0.186 0.82 0.67 0.99
Adenocarcinoma Ref. Ref. Ref.
Squamous cell carcinoma 0.91 0.79 1.05 0.89 0.77 1.02 0.116 0.83 0.72 0.95
Other non-small cell types 2.07 1.77 2.42 1.97 1.70 2.29 0.099 1.87 1.61 2.18
Small cell carcinoma 4.06 3.23 5.12 3.90 3.10 4.92 0.207 3.94 3.14 4.94
Large cell carcinoma 1.51 0.97 2.36 1.44 0.93 2.22 0.065 1.29 0.83 1.99
Carcinoida 0.02 0.00 0.18 0.02 0.00 0.15 0.764 1.53 0.87 2.70
Specified othera 0.41 0.03 6.63 0.74 0.06 9.27 0.627 2.30 0.29 18.35
Unspecified other 1.94 1.67 2.24 1.85 1.59 2.15 0.289 2.07 1.80 2.37
Abbreviations: FMI¼ fraction of missing information (for each respective variable
category, it denotes the proportion of the estimation that used imputed missing
information); LCI¼ lower confidence interval; OR¼ odds ratio; Ref¼ reference;
UCI¼ upper confidence interval. aFor these two groups, large differences are
apparent between the analysis under the missing stage¼ stage IV analysis and either
complete case analysis or multiple imputation. Both these groups were small and
had a particularly small proportion of patients with observed stage (o20%), most
of whom were in stage I/II. The above indicate that the missing stage¼ stage IV
assumption for patients with missing stage in these two groups is unlikely to be
reasonable; we nevertheless present findings for consistency.
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